Krishna K. Sharma

Dr. Krishna K. Sharma

College of Pharmacy, The Ohio State University, Columbus, Ohio, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSKrishna K. Sharma
Krishna K. Sharma
KSKomal Sharma
Komal Sharma
KRKamya Rao
Kamya Rao
ASAnku Sharma
Anku Sharma
GRGajanan K. Rathod
Gajanan K. Rathod
RJRahul Jain
Rahul Jain

5 December 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EOEmily A. O’bRien
Emily A. O’bRien
KSKrishna K. Sharma
Krishna K. Sharma
JBJacob Byerly-Duke
Jacob Byerly-Duke
LCLuis A. Camacho
Luis A. Camacho
BVBrett VanVeller
Brett VanVeller

1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSKrishna K. Sharma
Krishna K. Sharma
RRRavikant Ravi
Ravikant Ravi
IMIndresh Kumar Maurya
Indresh Kumar Maurya
AKAkshay Kapadia
Akshay Kapadia
SKShabana I. Khan
Shabana I. Khan
RJRahul Jain
Rahul Jain

17 April 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BWBrendan J. Wall
Brendan J. Wall
KSKrishna K. Sharma
Krishna K. Sharma
EOEmily A. O’brien
Emily A. O’brien
ADAaron Donovan
Aaron Donovan
BVBrett VanVeller
Brett VanVeller

1 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AKAkshay Kapadia
Akshay Kapadia
KSKrishna K. Sharma
Krishna K. Sharma
IMIndresh Kumar Maurya
Indresh Kumar Maurya
VSVarinder Singh
Varinder Singh
MKMadhu Khullar
Madhu Khullar
RJRahul Jain
Rahul Jain

12 December 2019 in Molecules
Verified
Journal Article
Open access
PDF file
RCRobert J. Cassell
Robert J. Cassell
KSKrishna K. Sharma
Krishna K. Sharma
HSHongyu Su
Hongyu Su
BCBenjamin R Cummins
Benjamin R Cummins
HCHaoyue Cui
Haoyue Cui
Richard M. Van RijnRichard M. Van Rijn
Richard M. Van Rijn
As tool compounds to study cardiac ischemia, the endogenous δ-opioid receptors (δOR) agonist Leu5-enkephalin and the more metabolically stable synthetic peptide (d-Ala2, d-Leu5)-enkephalin are frequently employed. However, both peptides have similar pharmacological profiles that restrict detailed investigation of the cellular mechanism of the δOR’s protective role during ischemic events. Thus, a need remains for δOR peptides with improved selectivity and unique signaling properties for investigating the specific roles for δOR signaling in cardiac ischemia. To this end, we explored substitution at the Phe4 position of Leu5-enkephalin for its ability to modulate receptor function and selectivity. Peptides were assessed for their affinity to bind to δORs and µ-opioid receptors (µORs) and potency to inhibit cAMP signaling and to recruit β-arrestin 2. Additionally, peptide stability was measured in rat plasma. Substitution of the meta-position of Phe4 of Leu5-enkephalin provided high-affinity ligands with varying levels of selectivity and bias at both the δOR and µOR and improved peptide stability, while substitution with picoline derivatives produced lower-affinity ligands with G protein biases at both receptors. Overall, these favorable substitutions at the meta-position of Phe4 may be combined with other modifications to Leu5-enkephalin to deliver improved agonists with finely tuned potency, selectivity, bias and drug-like properties.